Breaking Migrant Surge in Ceuta Prompts Spanish Government Appeal Court Dates for Elijah Bieniemy Postponed Amidst Mental Health Evaluation Turkey Expresses Interest in Post-UNIFIL Lebanon Security Initiative 30-Year Fixed Mortgage Rate Hits One-Year High Amid Economic and Geopolitical Factors North Carolina Program Addresses Internal Duties Amidst GM’s Leave

Thursday July 30, 2026

Reporter

NanoViricides

3Articles Published

5Communities Covered

Published Articles

Press Release

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Jul 23

Press Release

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Jul 13

Press Release

Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Jul 8